Request a Quote |

Press Release - Expansion of UK Facility into Biohub at Alderley Park

Cyprotex PLC
(“Cyprotex” or “the Company”)

Cyprotex to expand its UK facility into BioHub at Alderley Park

1st October 2013; Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation, announced today its plans for the expansion of its UK facility into BioHub, a new bioscience centre at AstraZeneca’s Alderley Park research campus near Manchester, England.

BioHub will provide Cyprotex with additional capacity for laboratories and office space. The new laboratories include fully equipped cell culture facilities and radiochemical handling capabilities enabling Cyprotex to continue its growth strategy into new areas supporting preclinical drug discovery projects.

This expansion follows highly encouraging growth figures for the business in the first six months of the year, with a revenue increase of 22.3% in H1 compared to the same period in 2012 and a record half yearly operating profit of £317,000. Performance remains strong across all of our geographical markets and our main service operations of high throughput ADME, customised ADME and toxicology.

Dr Anthony Baxter, Cyprotex’s Chief Executive Officer, comments: “As we continue to see significant growth in our business, it has been necessary to expand our facilities to meet the increased demand. We are therefore delighted to announce the signing of a lease for new cutting-edge facilities at BioHub in Alderley Park. The location of the facility is ideal for transport links, both by air and road, which is important as Cyprotex expands its international footprint.”

For further information:

Cyprotex PLC
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel

N+1 Singer (Nomad and broker to Cyprotex)
Tel: +44 (0)20 7496 3000
Shaun Dobson
Jenny Wyllie

FTI Consulting
Simon Conway
Mo Noonan
Tel: +44 (0) 20 7831 3113

Notes to Editors

About Cyprotex PLC

Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotech’s to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below: